Based on the increased ocular blood flow, PDE-5 inhibitors may affect diseases involving increased choroidal thickness, such as central serous chorioretinopathy, and may be a therapeutic option for other diseases caused by choroidal and/or retinal ischemia [14]. The gene discussed is PDE5A; the disease is retinal ischemia.